Biodesix (BDSX)
(Real Time Quote from BATS)
$1.77 USD
-0.03 (-1.67%)
Updated Sep 13, 2024 03:32 PM ET
After-Market: $1.77 0.00 (0.00%) 4:08 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
BDSX 1.77 -0.03(-1.67%)
Will BDSX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BDSX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BDSX
Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates
Organon (OGN) Surpasses Q2 Earnings Estimates
BDSX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Medpace (MEDP) Tops Q2 Earnings Estimates
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates
Other News for BDSX
Biodesix to Present at Two Investor Conferences in September
Biodesix Releases Updated Corporate Presentation Information
Buy Rating Justified: Biodesix’s Strong Q2 Performance and Growth Prospects
Strong Sales Growth and Market Position Justify Buy Rating for Biodesix
Buy Rating on Biodesix Affirmed Following Strong Q2 Performance and Positive Growth Indicators